AUPH
Aurinia Pharmaceuticals Inc
$15.35
-$0.19(-1.22%)
71
Overall
80
Value
60
Tech
73
Quality
Market Cap
$1.97B
Volume
598.09K
52W Range
$7.29 - $16.88
Target Price
$17.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $173.0K | $418.0K | $463.0K | $318.0K | $50.1M | $45.6M | $103.5M | $158.5M | $216.2M | $271.3M | ||
| Total Revenue | $173.0K | $418.0K | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $14.5M | $33.9M | $41.4M | $52.9M | -- | $1.1M | $5.7M | $14.1M | $28.2M | $32.7M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $-14.4M | $-33.5M | $-40.9M | $-52.5M | $50.1M | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $8.4M | $13.6M | $15.0M | $76.3M | $154.4M | $225.2M | $239.8M | $244.7M | $197.2M | $143.8M | ||
| Research & Development | -- | -- | -- | $52.9M | $50.3M | $51.1M | $18.5M | $49.6M | $20.8M | $32.5M | ||
| Research Expense | -- | -- | -- | -- | -- | -- | $18.5M | $49.6M | -- | -- | ||
| Selling, General & Administrative | $7.0M | $12.1M | $13.7M | $22.3M | $96.0M | $171.4M | $20.5M | $195.0M | $172.0M | $101.8M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | $20.5M | $195.0M | $172.0M | $101.8M | ||
| General & Administrative Expenses | $7.0M | $12.1M | $13.7M | $22.3M | $96.0M | $171.4M | $15.8M | -- | -- | -- | ||
| Salaries & Wages | $4.0M | $7.5M | $8.8M | $12.1M | $53.8M | $105.4M | $186.6M | $192.5M | -- | -- | ||
| Depreciation & Amortization | $1.5M | $1.5M | $1.3M | $1.1M | $1.3M | $2.1M | $15.8M | $13.3M | -- | -- | ||
| Depreciation & Amortization | $1.5M | $1.5M | $1.3M | $1.1M | $1.3M | $2.1M | $15.8M | $13.3M | -- | -- | ||
| Amortization | $1.5M | $1.4M | $1.3M | $1.1M | $1.3M | $2.1M | $15.8M | $13.3M | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | $6.8M | $574.0K | $1.5M | $8.4M | $4.3M | $9.5M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-22.8M | $-47.1M | $-55.9M | $-76.0M | $-104.3M | $-180.7M | $-111.5M | $-83.3M | $9.7M | $106.6M | ||
| EBITDA | $-21.8M | $-69.3M | $-51.7M | $-87.0M | $-101.4M | $-177.4M | $-106.4M | $-58.4M | $10.3M | $127.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $39.0K | -- | -- | -- | $2.8M | $4.8M | $4.3M | ||
| Intinc | $27.0K | $1.0M | $2.2M | $2.7M | $1.5M | $529.0K | $5.1M | $17.0M | $17.0M | $13.6M | ||
| Net Non-Operating Interest Income/Expense | $-27.0K | $-702.0K | $-2.2M | $-2.7M | $-1.5M | $-529.0K | $-5.1M | $14.2M | $12.1M | $9.2M | ||
| Gain on Sale of Securities | $1.1M | $-23.9M | $-9.9M | $-41.1M | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-508.0K | $-24.4M | $666.0K | $-14.9M | $-6.8M | -- | $-1.5M | $-8.4M | $-4.3M | -- | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | $1.5M | $8.4M | $4.3M | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | $23.1M | $1.6M | ||
| Special Income Charges | $1.6M | $503.0K | $236.0K | $1.2M | -- | -- | -- | -- | $-23.1M | $-1.6M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-23.3M | $-70.8M | $-53.0M | $-88.2M | $-102.8M | $-180.2M | $-106.4M | $-57.9M | $3.6M | $118.5M | ||
| Pre-Tax Income | $-23.3M | $-70.8M | $-53.0M | $-88.2M | $-102.8M | $-180.2M | $-106.4M | $-60.7M | $-1.2M | $114.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $73.0K | $144.0K | $-94.0K | $760.0K | $1.8M | $551.0K | $1.7M | $-173.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-23.3M | $-70.8M | $-53.1M | $-88.4M | $-102.7M | $-181.0M | $-108.2M | $-61.3M | $-2.9M | $287.2M | ||
| Net Income (Continuing Operations) | $-23.3M | $-70.8M | $-53.1M | $-88.4M | $-102.7M | $-181.0M | $-108.2M | $-61.3M | $-2.9M | $287.2M | ||
| Net Income (Discontinued Operations) | $-23.3M | $-70.8M | $-53.1M | $-88.4M | $-102.7M | $-181.0M | $-108.2M | $-61.3M | $-2.9M | $287.2M | ||
| Net Income (Common Stockholders) | $-23.3M | $-70.8M | $-53.1M | $-88.4M | $-102.7M | $-181.0M | $-108.2M | $-61.3M | $-2.9M | $287.2M | ||
| Normalized Income | $-15.5M | $-51.5M | $-38.7M | $-63.7M | $-102.9M | $-132.5M | $-78.2M | $-44.6M | $21.9M | $-57.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-23.0M | $-47.5M | $-56.4M | $-76.3M | $-154.4M | $-226.3M | $245.5M | $258.8M | $225.4M | $176.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $35.3M | $76.9M | $84.8M | $93.0M | $118.5M | -- | $141.9M | $143.2M | $143.1M | $134.4M | ||
| Average Shares Outstanding (Diluted) | $35.3M | $76.9M | $84.8M | $93.0M | $118.5M | -- | $141.9M | $143.2M | $146.2M | $138.7M | ||
| Shares Outstanding | $129.9M | $129.9M | $129.9M | $129.9M | $129.9M | $129.9M | $129.9M | $129.9M | $129.9M | $132.3M | ||
| Basic EPS | $-0.66 | $-0.92 | $-0.63 | $-1.33 | $-0.87 | -- | $-0.76 | $-0.54 | $0.04 | $2.14 | ||
| Basic EPS (Continuing Operations) | $-0.66 | $-0.92 | $-0.63 | $-1.33 | $-0.87 | -- | $-0.76 | $-0.54 | $0.04 | $2.14 | ||
| Diluted EPS | $-0.66 | $-0.92 | $-0.63 | $-1.33 | $-0.87 | -- | $-0.76 | $-0.54 | $0.04 | $2.07 | ||
| Diluted EPS (Continuing Operations) | $-0.66 | $-0.92 | $-0.63 | $-1.33 | $-0.87 | -- | $-0.76 | $-0.54 | $0.04 | $2.07 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | $19.0K | $-1.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | $5.7M | $14.1M | $28.2M | $32.7M | ||
| Other Gand A | $7.0M | $12.1M | $13.7M | $22.3M | $96.0M | $171.4M | $15.8M | -- | -- | -- | ||
| Rent And Landing Fees | $829.0K | $1.3M | $1.7M | $2.4M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | $1.6M | $502.0K | $236.0K | $1.2M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | $23.1M | $1.6M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUPH | $15.35 | -1.2% | 598.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aurinia Pharmaceuticals Inc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW